Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials NCT00769470), participants with early-stage HER2-positive breast cancer (N = 128) were recruited from 13 United States oncol...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurvitz, Sara A., Caswell-Jin, Jennifer L., McNamara, Katherine L., Zoeller, Jason J., Bean, Gregory R., Dichmann, Robert, Perez, Alejandra, Patel, Ravindranath, Zehngebot, Lee, Allen, Heather, Bosserman, Linda, DiCarlo, Brian, Kennedy, April, Giuliano, Armando, Calfa, Carmen, Molthrop, David, Mani, Aruna, Chen, Hsiao-Wang, Dering, Judy, Adams, Brad, Kotler, Eran, Press, Michael F., Brugge, Joan S., Curtis, Christina, Slamon, Dennis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673127/
https://www.ncbi.nlm.nih.gov/pubmed/33203854
http://dx.doi.org/10.1038/s41467-020-19494-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673127/
https://www.ncbi.nlm.nih.gov/pubmed/33203854
http://dx.doi.org/10.1038/s41467-020-19494-2

Ejemplares similares